Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘New GSK’ Raises Outlook After Shingrix Hits New Heights

Vaccine Leads Growth In New Slimline Company

Executive Summary

The company looks to be building momentum at last, with four more late-stage trial readouts expected in the second half of 2022.

You may also be interested in...



Europe’s Big Pharma Sails On Serenely Despite Choppy Economic Waters

The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.

Brii’s Cocktail Active Against Coronavirus Subvariants, But Will It Succeed On The Market?

The company announced data showing the two-antibody drug had strong activity against Omicron BA.4, BA.5 and BA.2.12.1, but on the US market it would compete against oral drugs.

Consumer Spin-Off Finally Achieved, GSK Will Weigh More M&A

GSK is entering a new era, and CEO Emma Walmsley looks likely to use new finances for more targeted M&A.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146776

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel